About Afimmune

Afimmune, headquartered in Dublin, Ireland, is a drug discovery and development company working on new medicines to improve the quality of life for people with rare and inflammatory diseases. Afimmune has assets in various stages of clinical and pre-clinical development. Afimmune pipeline

Latest News

June 10, 2022
Published by Melanie Hurley Iveagh at June 10, 2022
Categories

Data Showing Epeleuton As A Potential Treatment For Sickle Cell Disease Will Be Presented At The EHA 2022 Congress

Dublin, Ireland, 10 June 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at […]
Do you like it?0
Read more

More Press Releases

Publications and Conferences

May 13, 2022
Published by micadmin at May 13, 2022
Categories

EPELEUTON, A NOVEL SYNTHETIC SECOND GENERATION W-3 FATTY ACID, PROTECTS HUMANIZED SICKLE CELL MICE AGAINST HYPOXIA/REOXYGENATION ORGAN DAMAGE

Presentation during EHA2022: All (e)Poster presentations will be made available as of Friday, June 10, 2022 (09:00 CEST) and will be accessible for on-demand viewing until […]
Do you like it?0
Read more

Join our mailing list

Contact us

t: +353 1 2946380 e: [email protected]